NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021: Featured Updates to the NCCN Guidelines
Open accessAbstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targeted therapies, immunotherapies, and their respective biomarkers.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
For advanced NSCLC without targetable oncogenic mutations, ICIs are standard first-line therapy, used with or without chemotherapy according to tumour PD-L1 expression.
“Indeed, ICIs are the standard-of-care first-line treatment for advanced-stage NSCLCs that lack targetable oncogenic mutations, with or without chemotherapy depending on tumoural PD-L1 expression level161.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [161]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522 · see citing works
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,404 · see citing works
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · see citing works
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · see citing works
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508 · see citing works
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733 · see citing works
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617 · see citing works
Mok, T. S. K., Wu, Y.-L. L. C., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., de Castro, G., Srimuninnimit, V., Лактионов, К. К., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,319 · see citing works
Self-citationNivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063 · see citing works
Self-citationNivolumab plus ipilimumab in advanced non-small-cell lung cancer
Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910231 · Cited by 2,823 · see citing works
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798 · see citing works
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552 · see citing works
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503 · see citing works
Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
Wu, Y.-L. L. C., Tsuboi, M., He, J., John, T., Grohé, C., Majem, M., Goldman, J. W., Лактионов, К. К., Kim, S., Kato, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027071 · Cited by 1,820 · see citing works
Reck, M., Rodríguez–Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00149 · Cited by 1,670 · see citing works
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenégre, A., Barrios, C. H., Morise, M., Felip, E., Andric, Z. G., Geater, S. L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917346 · Cited by 1,667 · see citing works
Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3384 · Cited by 1,367 · see citing works
Self-citationMazières, J., Drilon, A. E. D. C., Lusque, A., Mhanna, L., Cortot, A. B., Mezquita, L., Thai, A. A., Mascaux, C., Couraud, S., Veillon, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz167 · Cited by 1,359 · see citing works
Self-citationNon–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Chirieac, L. R., D’Amico, T. A., DeCamp, M. M., Dilling, T. J., Dobelbower, M. C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0050 · Cited by 1,305 · see citing works
Self-citationHirsch, F. R., McElhinny, A., Stanforth, D., Ranger‐Moore, J., Jansson, M., Kulangara, K., Richardson, W., Towne, P., Hanks, D. A., Vennapusa, B., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2228 · Cited by 1,277 · see citing works
Gainor, J. F., Shaw, A. T., Sequist, L. V. D., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L. E., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,256 · see citing works
Garon, E. B., Hellmann, M. D., Rizvi, N. A., Carcereny, E., Leighl, N. B., Ahn, M.-J., Eder, J. P., Balmanoukian, A. S., Aggarwal, C., Horn, L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00934 · Cited by 1,231 · see citing works
Self-citationFirst-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Bauer, T. M., de Marinis, F., Felip, E., Goto, Y., Liu, G., Mazières, J., Kim, D., Mok, T. S. K., Polli, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027187 · Cited by 1,125 · see citing works
Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer
Wolf, J., Seto, T., Han, J., Reguart, N., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Hida, T., de Jonge, M. J. A., Orlov, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002787 · Cited by 1,004 · see citing works
Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer
Camidge, D. R., Kim, H. R., Ahn, M.-J., Yang, J. C.-H., Han, J.-Y., Lee, J.-S., Hochmair, M. J., Li, J. Y.-C., Chang, G.-C., Lee, K. H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810171 · Cited by 980 · see citing works
Self-citationEfficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
Drilon, A. E. D. C., Oxnard, G. R., Tan, D. S.-W., Loong, H. H.-F., Johnson, M. L., Gainor, J. F., McCoach, C. E., Gautschi, O. P., Besse, B., Cho, B. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2005653 · Cited by 833 · see citing works
Tsao, M., Kerr, K. M., Kockx, M. M., Beasley, M. B., Borczuk, A., Botling, J., Bubendorf, L., Chirieac, L. R., Chen, G., Chou, T., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.013 · Cited by 805 · see citing works
Self-citationLisberg, A., Cummings, A., Goldman, J. W., Bornazyan, K., Reese, N., Wang, T., Coluzzi, P., Ledezma, B., Mendenhall, M., Hunt, J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.03.035 · Cited by 580 · see citing works
Shaw, A. T., Riely, G. J., Bang, Y.-J., Kim, D.-W., Camidge, D. R., Solomon, B. J., Varella-Garcia, M., Iafrate, A. J., Shapiro, G. I., Usari, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz131 · Cited by 576 · see citing works
Self-citationDrilon, A. E. D. C., Siena, S., Dziadziuszko, R., Barlési, F., Krebs, M., Shaw, A. T., de Braud, F., Rolfo, C. D., Ahn, M., Wolf, J., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30690-4 · Cited by 533 · see citing works
Self-citationCamidge, D. R., Dziadziuszko, R., Peters, S., Mok, T. S. K., Noé, J., Nowicka, M., Gadgeel, S. M., Cheema, P. K., Pavlakis, N., de Marinis, F., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.007 · Cited by 492 · see citing works
Benayed, R., Offin, M. D., Mullaney, K. A., Sukhadia, P., Rios, K., Desmeules, P., Ptashkin, R. N., Won, H. H., Chang, J. C., Halpenny, D. F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0225 · Cited by 490 · see citing works
Self-citationSholl, L. M., Aisner, D. L., Varella-Garcia, M., Berry, L. D., Dias-Santagata, D., Wistuba, I. I., Chen, H., Fujimoto, J., Kugler, K., Franklin, W. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000516 · Cited by 430 · see citing works
Self-citationTsurutani, J., Iwata, H., Krop, I. E., Janne, P. A., Doi, T., Takahashi, S., Park, H., Redfern, C. H., Tamura, K., Wise-Draper, T. M., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1014 · Cited by 356 · see citing works
Camidge, D. R., Kim, H. R., Ahn, M., Yang, J. C., Han, J., Hochmair, M. J., Lee, K. H., Delmonte, A., Campelo, M. R. G., Kim, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00505 · Cited by 356 · see citing works
Self-citationFive-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs
Lin, J. J., Cardarella, S., Lydon, C., Dahlberg, S. E., Jackman, D. M., Janne, P. A., & Johnson, B. E. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.103 · Cited by 355 · see citing works
Self-citationAntonia, S. J., Borghaei, H., Ramalingam, S. S., Horn, L., de Castro, J., Płużański, A., Burgio, M. A., Garassino, M. C., Chow, L. Q. M., Gettinger, S. N., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30407-3 · Cited by 351 · see citing works
Self-citationJohung, K. L., Yeh, N., Desai, N. B., Williams, T. M., Lautenschlaeger, T., Arvold, N. D., Ning, M. S., Attia, A. A., Lovly, C. M., Goldberg, S. B., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0138 · Cited by 332 · see citing works
Self-citationOffin, M. D., Rizvi, H. A., Tenet, M., Ni, A., Sánchez-Vega, F., Li, B. T., Drilon, A. E. D. C., Kris, M. G., Rudin, C. M., Schultz, N. D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1102 · Cited by 329 · see citing works
Self-citationSholl, L. M., Hirsch, F. R., Hwang, D. M., Botling, J., López‐Ríos, F., Bubendorf, L., Mino-Kenudson, M. A., Roden, A. C., Beasley, M. B., Borczuk, A., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.019 · Cited by 284 · see citing works
Leighl, N. B., Hellmann, M. D., Hui, R., Carcereny, E., Felip, E., Ahn, M., Eder, J. P., Balmanoukian, A. S., Aggarwal, C., Horn, L., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30500-9 · Cited by 174 · see citing works
Self-citationPacheco, J. M., Gao, D., Smith, D. E., Purcell, T., Hancock, M. J., Bunn, P. A., Robin, T. P., Liu, A. J., Karam, S. D., Gaspar, L. E., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.014 · Cited by 147 · see citing works
Self-citationSmit, E. F., Nakagawa, K., Nagasaka, M., Felip, E., Goto, Y., Li, B. T., Pacheco, J. M., Murakami, H., Barlési, F., Saltos, A. N., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9504 · Cited by 117 · see citing works
Borghaei, H., Langer, C. J., Paz‐Ares, L., Rodríguez‐Abreu, D., Halmos, B., Garassino, M. C., Houghton, B., Kurata, T., Cheng, Y., Lin, J., et al. (2020) · Cancer · doi:10.1002/cncr.33142 · Cited by 115 · see citing works
Self-citationD’Angelo, A., Sobhani, N., Chapman, R., Bagby, S., Bortoletti, C., Traversini, M., Ferrari, K., Voltolini, L., Darlow, J., & Roviello, G. (2020) · Cancers · doi:10.3390/cancers12113293 · Cited by 107 · see citing works
Nadal, E., Massutí, B., Dómine, M., García‐Campelo, R., Cobo, M., & Felip, E. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02310-2 · Cited by 103 · see citing works
Khunger, A., Khunger, M., & Velcheti, V. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466618767611 · Cited by 81 · see citing works
Gainor, J. F., Curigliano, G., Kim, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9515 · Cited by 74 · see citing works
Sands, J. M., Nguyen, T. T., Shivdasani, P., Sacher, A. G., Cheng, M. L., Alden, R. S., Janne, P. A., Kuo, F. C., Oxnard, G. R., & Sholl, L. M. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.12.005 · Cited by 60 · see citing works
The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer
Zhao, D., Chen, X., Qin, N., Su, D., Zhou, L., Zhang, Q., Li, X., Zhang, X., Jin, M., & Wang, J. (2017) · Scientific Reports · doi:10.1038/srep40374 · Cited by 58 · see citing works
Lam, V. K. L., Tran, H. T., Banks, K. C., Lanman, R. B., Rinsurongkawong, W., Peled, N., Lewis, J., Lee, J. J., Roth, J. A., Roarty, E. B., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.08.020 · Cited by 58 · see citing works
Singhi, E. K., Horn, L., Sequist, L. V. D., Heymach, J. V., & Langer, C. J. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237821 · Cited by 45 · see citing works
Mu, Y., Yang, K., Hao, X., Wang, Y., Wang, L., Liu, Y., Lin, L., Li, J., & Xing, P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00603 · Cited by 33 · see citing works
Sesma, A., Pardo, J., Cruellas, M., Gálvez, E. M., Ruiz, M. G., Isla, D., Martínez‐Lostao, L., Ocáriz, M., Paño, J. R., Quílez, E., et al. (2020) · Cancers · doi:10.3390/cancers12102974 · Cited by 28 · see citing works
Auliac, J. B., Bayle, S., Dô, P., et al. (2020) · Cancers · doi:10.3390/cancers12123608 · Cited by 28 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549 · see citing works
Li, W., Xiong, A., Yang, N., Fan, H., Yu, Q., Zhao, Y., Wang, Y., Meng, X., Wu, J., Wang, Z., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00731 · Cited by 40 · see citing works
Self-citationNagasaka, M., Ohe, Y., Zhou, C., Choi, C.-M., Yang, N., Liu, G., Felip, E., Pérol, M., Besse, B., Nieva, J., et al. (2023) · Future Oncology · doi:10.2217/fon-2022-1059 · Cited by 32 · see citing works
- Authors
- Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., Dilling, T. J., Dowell, J., Gettinger, S., Gubens, M. A., Hegde, A., Hennon, M., Lackner, R. P., Lanuti, M., Leal, T. A., Lin, J., Loo Jr, B. W., Lovly, C. M., Martins, R. G., Massarelli, E., Morgensztern, D., Ng, T., Otterson, G. A., Patel, S. P., Riely, G. J., Schild, S. E., Shapiro, T. A., Singh, A. P., Stevenson, J., Tam, A., Yanagawa, J., Yang, S. C., Gregory, K. M., & Hughes, M.
- Affiliations
- Johns Hopkins University (US)
- Seattle Cancer Care Alliance (US)
- University of Colorado Cancer Center (US)
- Huntsman Cancer Institute (US)
- Fox Chase Cancer Center (US)
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University (US)
- 7Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;
- The University of Texas MD Anderson Cancer Center (US)
- Dana-Farber Brigham Cancer Center (US)
- Duke Cancer Institute (US)
- Moffitt Cancer Center (US)
- The University of Texas Southwestern Medical Center (US)
- Smilow Cancer Hospital (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- 15O'Neal Comprehensive Cancer Center at UAB;
- Roswell Park Comprehensive Cancer Center (US)
- Fred and Pamela Buffett Cancer Center (US)
- Massachusetts General Hospital (US)
- University of Wisconsin Carbone Cancer Center (US)
- University of Michigan (US)
- 21Stanford Cancer Institute;
- Vanderbilt-Ingram Cancer Center (US)
- City Of Hope National Medical Center (US)
- Barnes-Jewish Hospital (US)
- University of Tennessee Health Science Center (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- University of California San Diego (US)
- Memorial Sloan Kettering Cancer Center (US)
- Mayo Clinic (US)
- Abramson Cancer Center (US)
- Cleveland Clinic (US)
- UCLA Jonsson Comprehensive Cancer Center (US)
- National Comprehensive Cancer Network (US)
- ORCID
- Ettinger, David S.
- Wood, Douglas E.
- Aisner, Dara L.
- Akerley, Wallace
- Bauman, Jessica R.
- Bharat, Ankit
- Chang, Joe Y.
- Chirieac, Lucian R.
- Dilling, Thomas J.
- Dowell, Jonathan
- Gettinger, Scott
- Gubens, Matthew A.
- Hegde, Aparna
- Lanuti, Michael
- Leal, Ticiana A.
- Lin, Jules
- Lovly, Christine M.
- Martins, Renato G.
- Massarelli, Erminia
- Morgensztern, Daniel
- Otterson, Gregory A.
- Patel, Sandip P.
- Riely, Gregory J.
- Schild, Steven E.
- Shapiro, Theresa A.
- Singh, Aditi P.
- Tam, Alda
- Yanagawa, Jane
- Yang, Stephen C.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2021-03
- Volume
- 19
- Issue
- 3
- Pages
- 254-266
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W3135105663
- Cited by
- 948
- References
- 55
- Citations by year
- 2026: 31 · 2025: 78 · 2024: 180 · 2023: 249 · 2022: 321 · 2021: 88 · 2012: 1
- FWCI
- 137.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of the National Comprehensive Cancer Network (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Comprehensive Cancer Network
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- non-small cell lung cancer, targeted therapy, immunotherapy, biomarkers, cancer management
- MeSH terms
- Carcinoma, Non-Small-Cell Lung, Humans, Immunotherapy, Lung Neoplasms, Biomarkers, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
